Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Journal of Clinical Investigation

• Publication date

  1995-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1172/JCI117717PMID 7860752PMCID PMC295538
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E.

  1994cited by this paper
• Effect of gemfibrozil on adipose tissue and muscle lipoprotein lipase.

  1993cited by this paper
• An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphisms.

  1993cited by this paper
• Transcriptional regulation of human apolipoprotein genes ApoB, ApoCIII, and ApoAII by members of the steroid hormone receptor superfamily HNF-4, ARP-1, EAR-2, and EAR-3.

  1992cited by this paper
• Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors.

  1992cited by this paper
• Isolation and culturing of hepatocytes from human livers

  1992cited by this paper
• Regulation of gene expression by fatty acids and fibric acid derivatives: an integrative role for peroxisome proliferator activated receptors. The Belgian Endocrine Society Lecture 1992.

  1992cited by this paper
• Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors

  1992cited by this paper
• Perturbation of developmental gene expression in rat liver by fibric acid derivatives: lipoprotein lipase and alpha-fetoprotein as models.

  1992cited by this paper
• Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids.

  1992cited by this paper
• Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.

  1992cited by this paper
• Antagonism between apolipoprotein AI regulatory protein 1, Ear3/COUP-TF, and hepatocyte nuclear factor 4 modulates apolipoprotein CIII gene expression in liver and intestinal cells

  1992cited by this paper
• Biochemistry of peroxisomes.

  1992cited by this paper
• Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor.

  1992cited by this paper
• The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene.

  1992cited by this paper
• Maternal Clofibrate Administration Amplifies Fetal Peroxisomes

  1991cited by this paper
• Induction of acyl-CoA oxidase and cytochrome P450IVA1 RNA in rat primary hepatocyte culture by peroxisome proliferators.

  1991cited by this paper
• Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein.

  1990cited by this paper
• Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

  1990cited by this paper
• Promoter elements and factors required for hepatic and intestinal transcription of the human ApoCIII gene.

  1990cited by this paper
• Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice.

  1990cited by this paper
• Biochemical mechanisms of induction of hepatic peroxisome proliferation.

  1989cited by this paper
• Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration.

  1989cited by this paper
• Influence of development, estrogens, and food intake on apolipoprotein A-I, A-II, and E mRNA in rat liver and intestine.

  1989cited by this paper
• A regulatory element in the ApoCIII promoter that directs hepatic specific transcription binds to proteins in expressing and nonexpressing cell types.

  1989cited by this paper
• UV-induced DNA damage is an intermediate step in UV-induced expression of human immunodeficiency virus type 1, collagenase, c-fos, and metallothionein

  1989cited by this paper
• Human apolipoprotein CIII gene expression is regulated by positive and negative cis-acting elements and tissue-specific protein factors.

  1988cited by this paper
• Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins.

  1988cited by this paper
• Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

  1987cited by this paper
• Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers.

  1987cited by this paper
• [Effect of bezafibrate on lipoprotein secretion by cultured human hepatocytes].

  1987cited by this paper
• Fibric acids: effects on lipids and lipoprotein metabolism.

  1987cited by this paper
• Effect of bezafibrate on lipoprotein secretion by cultured human hepatocytes.

  1987cited by this paper
• Isolation and analysis of nuclear RNA.

  1987cited by this paper
• [22] Isolation and analysis of nuclear RNA

  1987cited by this paper
• Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.

  1986cited by this paper
• Linkage, evolution, and expression of the rat apolipoprotein A-I, C-III, and A-IV genes.

  1986cited by this paper
• Transcription regulation of peroxisomal fatty acyl-CoA oxidase and enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase in rat liver by peroxisome proliferators.

  1986cited by this paper
• Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III.

  1985cited by this paper
• Quantification of apolipoprotein C-III in serum by a noncompetitive immunoenzymometric assay.

  1985cited by this paper
• Molecular cloning of cDNA for rat acyl-CoA oxidase.

  1984cited by this paper
• Reversible alteration of hepatic messenger RNA species for peroxisomal and non-peroxisomal proteins induced by the hypolipidaemic drug Wy-14,643.

  1983cited by this paper
• DNA polymorphism adjacent to human apoprotein A-1 gene: relation to hypertriglyceridaemia.

  1983cited by this paper
• Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

  1983cited by this paper
• Linkage of human apolipoproteins A-I and C-III genes

  1983cited by this paper
• The effect of human C apolipoproteins on the in vitro hepatic metabolism of triglyceride emulsions in the rat.

  1982cited by this paper
• HEPATIC AND RENAL EFFECTS OF PEROXISOME PROLIFERATORS: BIOLOGICAL IMPLICATIONS *

  1982cited by this paper
• Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells

  1982cited by this paper
• Metabolic pathways in peroxisomes and glyoxysomes.

  1981cited by this paper
• Quantitative determination of human apolipoprotein C-III by electroimmunoassay.

  1980cited by this paper
• Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat. Opposing effects of homologous apolipoprotein E and individual C apoproteins.

  1980cited by this paper
• Hypertriglyceridaemia associated with an abnormal triglyceride-rich lipoprotein carrying excess apolipoprotein C-III-2.

  1979cited by this paper
• Increase in lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis.

  1979cited by this paper
• The immediate and long term effects of clofibrate on the metabolism of the perfused rat liver.

  1979cited by this paper
• Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

  1979cited by this paper
• Apolipoprotein C-II and C-III levels in hyperlipoproteinemia.

  1979cited by this paper
• Effect of clofibrate on postheparin plasma triglyceride lipase activities in patients with hypertriglyceridemia.

  1977cited by this paper
• HIGH-YIELD PREPARATION OF ISOLATED RAT LIVER PARENCHYMAL CELLS

  1969cited by this paper

• Reversibly reduced lipoprotein lipase in APOA5 c.553G>T-related hypertriglyceridemia successfully treated with pemafibrate

  2026cites this paper
• Apolipoprotein C-III: Risk-factor, Regulator of Triglyceride-rich Lipoprotein Metabolism and Therapeutic Target

  2026cites this paper
• Selective PPARα Modulator (SPPARMα) in the Era of the MASLD Pandemic: Current Insights and Future Prospects.

  2025cites this paper
• Fenofibrate differentially activates PPARα-mediated lipid metabolism in rat kidney and liver

  2025cites this paper
• Fenofibrate Treatment Inhibits Very-Low-Density Lipoprotein Transport Vesicle Formation by Reducing Sar1b Protein Expression

  2025cites this paper
• Lipoprotein lipase as a target for obesity/diabetes related cardiovascular disease

  2024cites this paper
• Efficacy of Pemafibrate Versus Fenofibrate Administration on Serum Lipid Levels in Patients with Dyslipidemia: Network Meta-Analysis and Systematic Review

  2023cites this paper
• An insight to treat cardiovascular diseases through phytochemicals targeting PPAR-α

  2023cites this paper
• Gamma‐glutamyl transferase predicts pemafibrate treatment response in non‐alcoholic fatty liver disease

  2023cites this paper
• Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis

  2023cites this paper
• α-Lactalbumin Peptide Asp-Gln-Trp Ameliorates Hepatic Steatosis and Oxidative Stress in Free Fatty Acids-Treated HepG2 Cells and High-Fat Diet-Induced NAFLD Mice by Activating the PPARα Pathway.

  2023cites this paper
• Strategies for Therapeutic Amelioration of Aberrant Plasma Zn2+ Handling in Thrombotic Disease: Targeting Fatty Acid/Serum Albumin-Mediated Effects

  2022cites this paper
• Mechanistic insights into the peroxisome proliferator-activated receptor alpha as a transcriptional suppressor

  2022cites this paper
• Plasma proteomics reveals crosstalk between lipid metabolism and immunity in dairy cows receiving essential fatty acids and conjugated linoleic acid

  2022cites this paper
• Is apoCIII-Lowering A Double-Edged Sword?

  2022cites this paper
• Impact of fenofibrate on NAFLD/NASH: a genetic perspective.

  2022cites this paper
• Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention

  2022cites this paper
• Discovery of analogues of non-β oxidizable long-chain dicarboxylic fatty acids as dual inhibitors of fatty acids and cholesterol synthesis: Efficacy of lead compound in hyperlipidemic hamsters reveals novel mechanism.

  2021cites this paper
• Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?

  2021cites this paper
• ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets

  2021cites this paper
• FABP regulates fatty acid metabolism and oxidative response via PPARα/RXR signaling in Litopenaeus vannamei following environmental exposure of clofibric acid

  2021cites this paper
• The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans

  2020influential citation
• Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases

  2020cites this paper
• Effect of pemafibrate on fatty acid levels and liver enzymes in non‐alcoholic fatty liver disease patients with dyslipidemia: A single‐arm, pilot study

  2020cites this paper
• Apolipoprotein CIII Deficiency Protects Against Atherosclerosis in Knockout Rabbits

  2020cites this paper
• HIGH INCIDENCE OF REDUCED SERUM HDL CHOLESTEROL IN DIABETIC PATIENTS TREATED WITH ROSIGLITAXONE AND FIBRATE

  2019cites this paper
• The Role of PPAR Gamma in the Onset of Type 2 Diabetes

  2019cites this paper
• Suppression of isoproterenol‐induced cardiotoxicity in rats by raspberry ketone via activation of peroxisome proliferator activated receptor‐&agr;

  2019cites this paper
• Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD

  2019cites this paper
• Recent developments in pharmacotherapy for hypertriglyceridemia: what’s the current state of the art?

  2019cites this paper
• A review of the studies on food-derived factors which regulate energy metabolism via the modulation of lipid-sensing nuclear receptors

  2019cites this paper
• Apolipoprotein CIII and diabetes. Is there a link?

  2019cites this paper
• Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia

  2019cites this paper
• Emerging evidences for the opposite role of apolipoprotein C3 and apolipoprotein A5 in lipid metabolism and coronary artery disease

  2019cites this paper
• The roles of PPARs in human diseases

  2018cites this paper
• Fenofibrate for Diabetic Retinopathy

  2018cites this paper
• Clinical Lipidology and the Prevention of Vascular Disease: Time for Personalized Therapy

  2018cites this paper
• Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism

  2018cites this paper
• Gemcabene, a first-in-class lipid-lowering agent in late-stage development, down-regulates acute-phase C-reactive protein via C/EBP-δ-mediated transcriptional mechanism

  2018cites this paper
• Triglyceride-Rich Lipoproteins.

  2018cites this paper
• Determination of Desaturase and Elongase Activity in Plasma of Diabetics

  2018cites this paper
• Lipoprotein lipase: Biosynthesis, regulatory factors, and its role in atherosclerosis and other diseases.

  2018cites this paper
• Postprandial Hyperchylomicronemia and Thin-Cap Fibroatheroma in Nonculprit Lesions: A Multivessel Optical Coherence Tomography Study

  2018cites this paper
• The whole transcriptome effects of the PPARα agonist fenofibrate on livers of hepatocyte humanized mice

  2018cites this paper
• Molecular Actions of PPARα in Lipid Metabolism and Inflammation.

  2018cites this paper
• Effects of K-877, a novel selective PPARα modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice.

  2017cites this paper
• Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: Results of the EFECTL Study

  2017cites this paper
• The yin and yang of apolipoprotein CIII.

  2017cites this paper
• Dyslipidaemia: Small triumph for fenofibrate therapy in dyslipidaemia

  2017cites this paper
• ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen

  2017cites this paper
• IN VITRO AND IN VIVO STUDIES OF APOLIPOPROTEIN CIII IN DIABETES

  2017cites this paper
• Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases.

  2017cites this paper
• Nuclear Receptors in Hepatic Glucose and Lipid Metabolism During Neonatal and Adult Life.

  2017cites this paper
• Distinct but complementary contributions of PPAR isotypes to energy homeostasis.

  2017cites this paper
• Mechanistic insight into nuclear receptor‐mediated regulation of bile acid metabolism and lipid homeostasis by grape seed procyanidin extract (GSPE)

  2017cites this paper
• Dyslipidemia management update

  2017cites this paper
• The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia.

  2017cites this paper
• Discovery of Novel Insulin Sensitizers: Promising Approaches and Targets

  2017cites this paper
• A Novel Role for RARα Agonists as Apolipoprotein CIII Inhibitors Identified from High Throughput Screening

  2017cites this paper
• New Era of Lipid-Lowering Drugs

  2016cites this paper
• Pharmakotherapie und Humanpharmakologische Untersuchungen bei Patienten mit DME (Diabetisches Makulaödem) und PDR (Proliferative Diabetische Retinopathie) anhand klinischer Parameter und inflammatorischer Biomarker

  2016cites this paper
• Role of autophagy in PPAR-induced changes in lipid metabolism in the liver

  2016cites this paper
• Targeting ApoC-III to Reduce Coronary Disease Risk

  2016cites this paper
• Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease

  2016cites this paper
• The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis.

  2016cites this paper
• Effect of Leptin Administration on Circulating Apolipoprotein CIII levels in Patients With Lipodystrophy.

  2016cites this paper
• Tri-m-cresyl phosphate and PPAR/LXR interactions in seabream hepatocytes: revealed by computational modeling (docking) and transcriptional regulation of signaling pathways.

  2016cites this paper
• The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia.

  2016cites this paper
• D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile

  2016cites this paper
• Apolipoprotein C-III: From Pathophysiology to Pharmacology.

  2015cites this paper
• Apolipoprotein C-III: From Pathophysiology to

  2015cites this paper
• Impact of fibrate therapy on plasma plasminogen activator inhibitor-1: a systematic review and meta-analysis of randomized controlled trials.

  2015cites this paper
• Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease

  2015cites this paper
• Therapeutic inhibition of apoC-III for the treatment of hypertriglyceridemia

  2015cites this paper
• Dietary Fenofibrate Reduces Hepatic Lipid Deposition by Regulating Lipid Metabolism in Yellow Catfish Pelteobagrus fulvidraco Exposed to Waterborne Zn

  2015cites this paper
• Integrated proteomic and miRNA transcriptional analysis reveals the hepatotoxicity mechanism of PFNA exposure in mice.

  2015cites this paper
• Fibrates: Risk Benefits and Role in Treating Dyslipidemias

  2015cites this paper
• Fenofibrate in cancer: mechanisms involved in anticancer activity (version 2; referees: 1 approved, 1 approved with reservations)

  2015cites this paper
• Biological characterization of liver fatty acid binding gene from miniature pig liver cDNA library.

  2015cites this paper
• The Liver in Metabolic Syndrome

  2014cites this paper
• PENGARUH PEMBERIAN EKSTRAK KULIT MANGGIS (GARCINIA MANGOSTANA L.) DAN SIMVASTATIN TERHADAP KADAR KOLESTEROL TOTAL TIKUS SPRAGUE DAWLEY DENGAN PAKAN TINGGI LEMAK

  2014cites this paper
• Cardiorespiratory fitness and visceral fat are key determinants of serum fibroblast growth factor 21 concentration in Japanese men.

  2014cites this paper
• Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?

  2014cites this paper
• Peroxisome Proliferator-Activated Receptor Alpha: Insight into the Structure, Function and Energy Homeostasis

  2014cites this paper
• trans-Caryophyllene is a natural agonistic ligand for peroxisome proliferator-activated receptor-α.

  2014cites this paper
• Mechanism of action of anti-hypercholesterolemia drugs and their resistance.

  2014cites this paper
• Hepatic molecular effects of rosiglitazone in human non‐alcoholic steatohepatitis suggest long‐term pro‐inflammatory damage

  2014cites this paper
• Peroxisome Proliferator-Activated Receptor (PPAR) α/γ Agonist

  2014cites this paper
• Rosiglitazone and bezafibrate modulate gene expression in a rat model of non-alcoholic fatty liver disease - A historical prospective

  2013cites this paper
• The role of fibrate treatment in dyslipidemia: an overview.

  2013cites this paper
• Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparα).

  2013cites this paper
• Hepatic PPARs: their role in liver physiology, fibrosis and treatment.

  2013cites this paper
• YÜKSEK KOLESTEROLLÜ DİYETLE BESLENEN RATLARDA GİNSENGİN TNF-α, LEPTİN VE BAZI SERUM LİPİD PARAMETRELERİ ÜZERİNE ETKİLERİ

  2013cites this paper
• Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

  2013cites this paper
• Absorption of Marine vs Non‐Marine sources of EPA and DHA

  2013influential citation
• Purinergic Signaling and Autophagy Regulate the Secretion of High-Density Lipoprotein and Hepatic Lipase

  2013cites this paper
• Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia.

  2012cites this paper
• Fenofibrate

  2012cites this paper
• Liver X receptor and peroxisome proliferator‐activated receptor as integrators of lipid homeostasis and immunity

  2012cites this paper
• Fenofibrate: Panacea for Aging-Related Conditions?

  2012cites this paper